By continuing, you agree to the Terms of Service.
This website uses cookies to enhance your browsing experience. Learn More.
Essential Cookies
Optional Cookies
Login
Logo for company Neurogene Inc.

Neurogene Inc. (NGNE)

NASDAQ Currency in USD
$20.08
+$1.48
+7.96%
Last Update: 11 Sept 2025, 20:00
$286.58M
Market Cap
-4.50
P/E Ratio (TTM)
Forward Dividend Yield
$6.88 - $74.49
52 Week Range

NGNE Stock Price Chart

Explore Neurogene Inc. interactive price chart. Choose custom timeframes to analyze NGNE price movements and trends.

NGNE Company Profile

Discover essential business fundamentals and corporate details for Neurogene Inc. (NGNE) to support your stock research and investment decisions.

Sector

Healthcare

Industry

Biotechnology

IPO Date

7 Mar 2014

Employees

107.00

CEO

Rachel L. McMinn

Description

Neurogene Inc. develops life-changing genetic medicines for patients and their families affected by neurological diseases. Its product candidate includes NGN-401, an investigational AAV9 gene therapy for the treatment of Rett syndrome; and NGN-101 to treat neuronal ceroid lipofuscinosis subtype 5 batten disease. The company is headquartered in New York, New York.

NGNE Financial Timeline

Browse a chronological timeline of Neurogene Inc. corporate events including earnings releases, dividend announcements, and stock splits.

Upcoming earnings on 7 May 2026

Upcoming earnings on 17 Nov 2025

EPS estimate is -$1.26.

Earnings released on 11 Aug 2025

EPS came in at -$1.05 surpassing the estimated -$1.15 by +8.70%.

Earnings released on 9 May 2025

EPS came in at -$1.08 falling short of the estimated -$1.05 by -2.86%.

Earnings released on 24 Mar 2025

EPS came in at -$0.99 surpassing the estimated -$1.04 by +4.81%.

Earnings released on 18 Nov 2024

EPS came in at -$1.19 surpassing the estimated -$1.22 by +2.46%.

Earnings released on 9 Aug 2024

EPS came in at -$1.09 falling short of the estimated -$1.02 by -6.86%, while revenue for the quarter reached $925.00K .

Earnings released on 10 May 2024

EPS came in at -$1.00 surpassing the estimated -$1.03 by +2.91%.

Earnings released on 26 Mar 2024

EPS came in at -$1.51 falling short of the estimated -$1.17 by -29.06%.

Stock split effective on 19 Dec 2023

Shares were split 1 : 4 , changing the number of shares outstanding and the price per share accordingly.

Earnings released on 14 Nov 2023

EPS came in at -$0.41 surpassing the estimated -$0.80 by +48.75%.

Stock split effective on 25 Sept 2023

Shares were split 1 : 5 , changing the number of shares outstanding and the price per share accordingly.

Earnings released on 10 Aug 2023

EPS came in at -$0.04 surpassing the estimated -$0.15 by +73.33%.

Earnings released on 30 Mar 2023

EPS came in at -$0.26 surpassing the estimated -$4.40 by +94.18%.

Earnings released on 30 Dec 2022

EPS came in at -$0.32 surpassing the estimated -$3.80 by +91.70%.

Earnings released on 30 Sept 2022

EPS came in at -$2.36 surpassing the estimated -$6.09 by +61.16%.

Earnings released on 29 Jun 2022

EPS came in at -$0.28 surpassing the estimated -$6.00 by +95.26%.

Earnings released on 31 Mar 2022

EPS came in at -$0.28 .

Earnings released on 30 Dec 2021

EPS came in at -$0.36 surpassing the estimated -$5.96 by +94.01%.

Earnings released on 29 Sept 2021

EPS came in at -$0.28 .

Earnings released on 29 Jun 2021

EPS came in at -$0.27 .

Earnings released on 31 Mar 2021

EPS came in at -$0.27 .

Earnings released on 31 Dec 2020

EPS came in at -$0.30 .

Earnings released on 30 Sept 2020

EPS came in at -$0.04 .

NGNE Stock Performance

Access detailed NGNE performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.

Explore Related Stocks

Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.

Discover More
Command Palette
Search for a command to run